Allogene Therapeutics

At Allogene, we’re advancing #CAR T therapy to transform lives. Through bold innovation in #celltherapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more. #allogeneic $ALLO Learn More: Allogene.com/Home

Executing with discipline, 2026 will deliver critical proof points that could validate allogeneic CAR T as the path to scalable, accessible cell therapy at biologic-like scale.

Experience the #allogeneic advantage. Our investigational AlloCAR T products aim to redefine the #CART landscape by addressing key limitations of autologous treatments – offering the potential for greater speed, scalability, and access for patients. #celltherapy $ALLO Discover the Allogeneic Advantage: Allogene.com/Home

Our own David Chang, MD, PhD, will take the stage at #AACR26 in San Diego to share the latest advances in allogeneic #CART and the path to delivering #CART cell therapy at scale. #allogeneic #celltherapy $ALLO Learn More: Allogene.com/Home

We aim to redefine #autoimmune disease treatment with ALLO-329, an investigational allogeneic #CART powered by Dagger® technology, which is designed to reduce or eliminate lymphodepletion. #celltherapy #allogeneic $ALLO Uncover the Potential of ALLO-329: Allogene.com/Pipeline

Pleased to report our Q4 and full year 2025 corporate update and business highlights. #allogeneic #CART #celltherapy $ALLO View Our Q4 and Full Year 2025 Update: ir.allogene.com/news-releases/…

Allogene is advancing ALLO-329 – an investigational “off-the-shelf” AlloCAR T™ product for #autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #CART #celltherapy #allogeneic $ALLO Uncover the Potential of ALLO-329: Allogene.com/Pipeline

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO Learn More About ALPHA3: allogene.com/alpha3/

1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an “off-the-shelf” #CART product to intervene early and potentially improve cure rates. $ALLO Learn More About ALPHA3: allogene.com/alpha3/

Congratulations to our Co-Founder and Executive Chairman, Arie Belldegrun, MD, on receiving the #PMWC2026 Luminary Award. His commitment to advancing breakthrough science and innovation is unwavering. Proud to celebrate this well-deserved honor. #celltherapy #CART $ALLO

Happening today: Our EVP of R&D and CMO, Zachary Roberts, MD, PhD, is speaking at @PMWCintl on the latest advances in allogeneic #CART products. @Arie_Belldegrun #PMWC26 #allogeneic #celltherapy $ALLO Learn More: pmwcintl.com/program

Look forward to participating in the TD Cowen Health Care Conference where we'll share updates on our investigational AlloCAR T pipeline in oncology and autoimmune disease. Webcast details are available in the Investors section of our website. $ALLO #CART #allogeneic #celltherapy Learn More: ir.allogene.com

After decades of uncertainty, patients with severe autoimmune disease may finally have a glimmer of hope. Check this out from our partners at #KatieCouricMedia: katiecouric.com/health/car-t-t…

We look forward to joining healthcare leaders, innovators, and investors at the TD Cowen Healthcare Conference to discuss the future of cell therapy and innovation in immune-mediated diseases. Find a link to the webcast on the IR section of our website. #CART #CellTherapy $ALLO Learn More: ir.allogene.com

At Allogene, we’re advancing #CAR T therapy to transform lives. Through bold innovation in #celltherapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more. #allogeneic $ALLO Learn More: Allogene.com/Home

Experience the #allogeneic advantage. Our investigational AlloCAR T™ products aim to redefine the #CART landscape by addressing key limitations of autologous treatments – offering the potential for greater speed, scalability, and access for patients. #celltherapy $ALLO Discover the Allogeneic Advantage: Allogene.com/Home

We are looking forward to participating in Citi’s 2026 Virtual Oncology Leadership Summit on Wednesday, Feb 18. Hear an update on our investigational #allogeneic #CART pipeline and corporate strategy. Webcast details are available on our IR site. #celltherapy $ALLO Learn More: ir.allogene.com

Allogene is advancing ALLO-329 – an investigational “off-the-shelf” AlloCAR T™ product for #autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #CART #celltherapy #allogeneic $ALLO Uncover the Potential of ALLO-329: Allogene.com/Pipeline

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO Learn More About ALPHA3: allogene.com/alpha3/